We are excited to announce positive Phase 1 data of our gene silencing therapy, which aims to silence Lipoproteina (#Lpa), a risk factor for #heartdisease. Read more here: bit.ly/34qQotr #SilenceisGOLDen #AmericanHeartMonth #biotech $SLN

In a small study released Wednesday, Silence Therapeutics showed that at a high dose, its RNAi technology could reduce a patient’s lp(a) levels by 98%. endpts.com/with-first-hum…

Fantastic news!! #sirna #lpa

#ICYMI: $SLN announced positive phase 1 data of our #genesilencing treatment, which aims to address the unmet need of those living with high levels of #Lipoproteina. Learn more at our late-breaking #ACC22 presentation: bit.ly/3HKZVKg #SilenceisGOLDen

Great to see a showcase of the UK as an AI powerhouse at The Foundation for Science and Technology #fstAI. Proud that Silence Therapeutics is putting AI/ML into action for siRNA drug discovery and development

Today is #LpaAwarenessDay. Lipoprotein (a) is an inherited condition that affects 1 in 5 people and increases your risk of cardiovascular disease. Talk to your doctor about testing for Lp(a) and how to reduce other #CVD 💔 risk factors. test.thefhfoundation.org #KnowLpa

Today is the first ever #LpaAwarenessDay. We’re grateful to have met many members of this disease community through our Lp(a) clinical program. We are committed to using our gene-silencing science to better serve your needs: bit.ly/3N2fPmm

Tomorrow, Dr. Steven E. Nissen of the Cleveland Clinic will be presenting the phase 1 APOLLO Trial data for our investigational siRNA therapy for high #Lpa. Get up to speed on the science: bit.ly/3IdINNo #SilenceIsGOLDen

The #lipid lowering world is changing before our eyes! #siRNA in the hyperLPA #therapy. Looking forward to seeing the results of the APOLLO trial. Silence Therapeutics Roger Blumenthal Pablo Corral MD @cpcannon Sam Tsimikas, MD Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 Viet Le DMSc PA-C FACC FAHA HF-Cert Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 Felice Gragnano Dr Meral Kayikcioglu

Attention #ACC22 early birds! Our APOLLO phase 1 #Lpa data will be presented this morning at 8:45 ET, during the JAMA Late-Breaking Clinical Trials session. Grab a coffee and tune in. #SilenceIsGOLDen

Lipoprotein(a) has been deemed important but inactionable for years. In addition to other meds in development, new data from ⁦Silence Therapeutics⁩ siRNA at #ACC22 in healthy participants with increased lipoprotein(a) notes suppression up to 98%! ⁦@TheFHFoundation⁩

In a phase 1 study of participants with elevated Lp(a) levels and no known cardiovascular disease, the siRNA SLN360 was well tolerated, and a dose-dependent lowering of plasma Lp(a) concentrations was observed. ja.ma/3qU3kQB #ACC22

Great to be back at #EASCongress2022 in person in Milan. Looking forward to a stimulating three days Silence Therapeutics European Atherosclerosis Society

Come and join my group in Milan! Five year research position. Open to multiple profiles. Machine learning researchers interested in large-scale imaging, genetics and health-research apply! Attractive 90% tax exemption for people new or returning to Italy. careers.humantechnopole.it/o/bioinformati…

Yesterday we announced the initiation of dosing in healthy volunteers in the RestorAATion clinical trial program, which is investigating WVE-006 for #AATD. WVE-006 is the first #RNAediting candidate ever to be evaluated in the humans. Click below to read more. $WVE

Calling #oligonucleotide therapeutics folks - please submit topics you would like to see on the agenda at the DIA oligo-based therapeutics meeting in Oct 2024 - we're putting the meeting together now and it's going to be a good one! diaglobal.org/conference-lis… #Oligo24

Drug discovery people in pharma and biotech - here's something for you: theproductcompound Come and learn what product people and product mindset can bring to the work we do theproductcompound.com linkedin.com/groups/1297118…

We’re hosting our first meetup for Product People and those involved in early R&D in pharma/biotech on June 18th in London Kings Cross. Come down and contribute to the discussion on how Product can bring value to the drug development pipeline! 🚀 eventbrite.co.uk/e/the-product-…

Thank you to Mark Edbrooke, Daniel Swerdlow, Catherine Wilson and Peter Oliver for your insightful talks at yesterday's #CamNTF event! Your expertise in nucleic acid therapeutics is truly inspiring. #Grateful #FutureOfHealthcare